ORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

ORIC Pharmaceuticals announced that Dr. Jacob Chacko, CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:00 p.m. ET. The presentation can be accessed via the investor section of their website, with a replay available for 30 days post-event.

ORIC focuses on overcoming therapeutic resistance in cancer with key candidates including ORIC-101, in Phase 1b trials, and other products targeting various cancers. For more information, visit oricpharma.com.

SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 3:00 p.m. ET.

A live webcast of the company presentation will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 30 days following the event.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials in combination with (1) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors and (2) Xtandi (enzalutamide) in metastatic prostate cancer. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer.. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.

Investor Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

FAQ

When will ORIC Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

ORIC Pharmaceuticals will present on January 11, 2022, at 3:00 p.m. ET.

How can I watch ORIC Pharmaceuticals' presentation at the conference?

You can access a live webcast of the presentation through the investor section of ORIC's website.

What is ORIC Pharmaceuticals focusing on in oncology?

ORIC Pharmaceuticals focuses on developing treatments to address mechanisms of therapeutic resistance in cancer.

What is ORIC-101 and its significance?

ORIC-101 is a lead product candidate targeting glucocorticoid receptor resistance in various solid tumors, currently in Phase 1b trials.

What are other product candidates being developed by ORIC Pharmaceuticals?

Other candidates include ORIC-533, ORIC-114, and ORIC-944, targeting different cancer resistance mechanisms.